Jeonjinbio전진바이오팜
110020 · KOSDAQ · ₩110020 · 전진바이오팜
₩2,085▲ ₩40 (1.96%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 26.0% | 27.6% | 31.4% | 31.1% | 25.2% | 42.4% |
| Operating margin | −3.0% | −2.5% | 6.0% | −7.9% | −40.8% | −94.3% |
| Net margin | −2.2% | −1.4% | 22.6% | −41.1% | −40.5% | −65.6% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +0.1% | −28.9% | +22.9% | +101.2% | +142.5% | — |
| Operating income growth | −20.5% | −129.6% | +193.0% | +60.8% | −4.9% | — |
| Net income growth | −56.8% | −104.5% | +167.5% | −104.2% | −49.6% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −1.8% | −1.1% | 36.4% | −81.9% | −31.1% | −19.5% |
| Return on assets | −1.7% | −1.0% | 23.8% | −36.2% | −14.8% | −8.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 8.7% | 6.3% | 6.7% | 184.6% | 87.9% | 129.9% |
| Net debt to equity | — | −36.8% | −35.5% | 119.7% | 49.5% | −17.5% |
| Current ratio | 795.8% | 1,083.1% | 934.0% | 69.3% | 59.1% | 115.6% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Jeonjinbio / 전진바이오팜 / 110020 / KRX:110020
Source: KRX statistical information